Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Aspart (NovoLog) vs Insulin Degludec (Tresiba)
An educational, source-based comparison of Insulin Aspart (NovoLog) and Insulin Degludec (Tresiba) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management
- • FDA-approved.
- • Hypoglycemia is the principal risk.
Ultra-long-acting basal insulin with >42-hour duration.
Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.
- Basal insulin therapy
- Flexible dosing schedules
- Reduced nocturnal hypoglycemia
- • FDA-approved.
- • Steady state reached after ~3 days.
Insulin Aspart (NovoLog) vs Insulin Degludec (Tresiba) — Key differences
- Class: Insulin Aspart (NovoLog) is classified as Insulin Analog · Endocrine, while Insulin Degludec (Tresiba) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Aspart (NovoLog) — prandial coverage; Insulin Degludec (Tresiba) — basal insulin therapy.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.